In Depth 15 Feb 2024
Biogen: how is the biotech giant pivoting from a failed Alzheimer’s drug?
Learn more about Biogen’s strategic realignment from Aduhelm’s controversy to Leqembi’s promise in Alzheimer’s treatment.
Search Results for: Alzheimer's
In Depth 26 Oct 2023
Behind closed doors: The unseen controversies and scandals in Alzheimer’s drug trials
Alzheimer’s disease is the most common form of dementia – which currently affects more than 55 million people globally – making up 60% to 70% of cases. It is a complex disease, encompassing multiple interrelated and progressive destructive processes in the brain, resulting in neuron damage that extends to parts of the brain that enable […]
Best in Biotech 12 Jun 2023
Six advancements in Alzheimer’s research over the past year
The most common cause of dementia, Alzheimer’s disease, is a brain disorder that is characterized by cognitive decline which often manifests itself through memory loss, feelings of disorientation and difficulty making decisions. Alzheimer’s occurs when there is an excessive accumulation of proteins in the brain, a hallmark feature of the disease. These proteins, namely, amyloid […]
News and Trends 16 May 2023
Researchers’ mutation discovery offers new Alzheimer’s hope
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder affecting tens of millions of people worldwide, and it is the most common cause of dementia. Early-onset AD is typically associated with mutations in the genes APP, PSEN1, and PSEN2, leading to a more aggressive form of the disease with atypical symptoms. In contrast, the newly discovered […]
ADVERTISEMENT
News and Trends 15 May 2023
Alzheimer’s drugs could result from immune brain cell discovery
A recent study published in Nature Neuroscience indicates that, contrary to common belief, the immune cells of the brain, known as microglia, are not all the same. Researchers found that a unique microglial subset with unique features and function is important for establishing proper cognitive functions in mice. Evidence for such microglial subsets exists also […]
News and Trends 9 May 2023
Ultra-long protein fibrils could help with early Alzheimer’s diagnosis
The early diagnosis and treatment of dementia such as Alzheimer’s disease is still a big challenge. It is already known that certain proteins in the cerebrospinal fluid can be used to diagnose Alzheimer’s disease. However, the current detection methods for such biomarkers by means of biochemical tests can only confirm and quantify the presence of […]
News and Trends 9 Feb 2023
Talking about Alzheimer’s disease: current drugs, clinical trials, and the pipeline
Sometimes, there’s an interview that we do that’s just a bit long for the regular podcast. So we’re going to start an occasional series of podcasts where we look a bit more in depth at a condition, and what’s the current state of affairs in treatment. In this podcast, the first, we take a closer […]
News and Trends 27 Jan 2023
EMA accepts Marketing Authorization Application for lecanemab to treat early Alzheimer’s disease
BioArctic AB’s partner Eisai says the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab. Lecanemab, known as LEQEMBI in the U.S., is an investigational anti-amyloid beta (Aβ) protofibril antibody, for the treatment of early Alzheimer’s disease (mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD dementia) with confirmed […]
News and Trends 22 Dec 2022
Watch: Norway’s Pre Diagnostics looks to early detection of Alzheimer’s
Pre Diagnostics AS is a new Norwegian company developing and commercializing an innovative and effective diagnostic test for Alzheimer’s disease (AD). Founded by an experienced biotech team, Pre Diagnostics owns the licensed rights to a patent-protected new diagnostic test from the Norwegian university hospital AHUS. The company said it will pursue cost-efficient product development with […]
News and Trends 30 Nov 2022
‘Best hope yet’ as results from Alzheimer’s drug trial reveal huge step forward
A huge step forward in dementia research has been hailed a truly historic moment by researchers working to find a cure for people with Alzheimer’s Disease. This is the first time a drug being trialed, lecanemab, has shown a reduction in the disease in the brain while slowing memory decline. Dr Susan Kohlhaas, director of […]
News and Trends 20 Oct 2022
Tiziana Life Sciences looks to phase 1 trial for intranasal Alzheimer’s drug
Tiziana Life Sciences Ltd. says it plans to submit an investigational new drug (IND) application for a phase 1 trial of intranasal foralumab in Alzheimer’s disease patients. It comes after the company received an affirmative written response from the FDA on a pre-investigational new drug application (PIND). Tiziana plans on filing the IND for Alzheimer’s […]
More News! 10 Oct 2022
Positive data indicates likely therapeutic effect of Alzheimer’s drug
Positive phase 2a clinical data from an Alzheimer’s disease (AD) biomarker study, has been announced today (October 10). Actinogen Medical Limited shared the news that its study validates its planned program for Xanamem, a potential drug for the disease. The biomarker study was conducted in 72 patients with available blood biomarker samples from the prior […]